Valbiotis SA (ALVAL.PA)

5.04 €

-0.20 (-3.82%)
Rating:
Recommendation:
-
Symbol ALVAL.PA
Price 5.04 €
Beta 0.185
Volume Avg. 0.05M
Market Cap 62.545M
Shares () -
52 Week Range 2.82-6.28
1y Target Est -
DCF Unlevered ALVAL.PA DCF ->
DCF Levered ALVAL.PA LDCF ->
ROE -89.04% Strong Sell
ROA -45.24% Strong Sell
Operating Margin -
Debt / Equity 53.74% Buy
P/E -4.24 Strong Sell
P/B -
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades


Mr. Sebastien Peltier HDR, Ph.D.
Healthcare
Biotechnology
Paris

Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.